Wrist fractures · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes wrist fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.9 [0.13, 6.04]
Studies not reported
Very low
Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.54, 2.18]
Studies not reported
Very low
Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.56 [0.2, 1.61]
Studies not reported
Moderate
Hip Fracture · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Wrist fractures · postmenopausal women at lower risk of fractures1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 1.41 [0.81, 2.47]
Studies not reported
Low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Clinical vertebral fractures · postmenopausal women with a higher risk for fracturesa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐vertebral fractures · postmenopausal women with a higher risk for fracturesa
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (low certainty).
1 finding from 1 review
RR 1.07 [0.72, 1.58]
Studies not reported
Low
Hip Fracture · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes hip fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.93 [0.17, 5.19]
Studies not reported
Very low
All symptomatic CMV disease · solid organ transplant recipients
Antiviral prophylaxis leads to lower CMV disease: all symptomatic CMV disease compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death associated with CMV disease · solid organ transplant recipients
Ganciclovir showed no clear difference in death due to CMV disease compared with aciclovir (moderate certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Ganciclovir showed no clear difference in all‐cause death compared with aciclovir (moderate certainty).
1 finding from 1 review
Acute rejection · solid organ transplant recipients
Ganciclovir showed no clear difference in acute rejection compared with aciclovir (high certainty).
1 finding from 1 review
Graft loss · solid organ transplant recipients
Ganciclovir showed no clear difference in graft loss compared with aciclovir (moderate certainty).
1 finding from 1 review
Opportunistic infections: other viral infections · solid organ transplant recipients
Ganciclovir showed no clear difference in opportunistic infections: other viral infections compared with aciclovir (moderate certainty).
1 finding from 1 review
Leucopenia · solid organ transplant recipients
Ganciclovir may leads to higher leucopenia compared with aciclovir (low certainty).
1 finding from 1 review
Kidney dysfunction · solid organ transplant recipients
Ganciclovir showed no clear difference in kidney dysfunction compared with aciclovir (moderate certainty).
1 finding from 1 review
CMV disease · solid organ transplant recipients
Valaciclovir showed no clear difference in CMV disease compared with ganciclovir or valganciclovir (low certainty).
1 finding from 1 review